AU2003224742A1 - Method of administering buprenorphine to treat depression - Google Patents

Method of administering buprenorphine to treat depression

Info

Publication number
AU2003224742A1
AU2003224742A1 AU2003224742A AU2003224742A AU2003224742A1 AU 2003224742 A1 AU2003224742 A1 AU 2003224742A1 AU 2003224742 A AU2003224742 A AU 2003224742A AU 2003224742 A AU2003224742 A AU 2003224742A AU 2003224742 A1 AU2003224742 A1 AU 2003224742A1
Authority
AU
Australia
Prior art keywords
depression
buprenorphine
treat depression
administering buprenorphine
patients suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003224742A
Other languages
English (en)
Inventor
Robert F. Kaiko
Ramiro Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of AU2003224742A1 publication Critical patent/AU2003224742A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2003224742A 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression Abandoned AU2003224742A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
US60/366,358 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (1)

Publication Number Publication Date
AU2003224742A1 true AU2003224742A1 (en) 2003-10-08

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003224742A Abandoned AU2003224742A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Country Status (12)

Country Link
US (1) US20030181475A1 (enExample)
EP (1) EP1485051B1 (enExample)
JP (1) JP2005528359A (enExample)
AT (1) ATE394097T1 (enExample)
AU (1) AU2003224742A1 (enExample)
CY (1) CY1108217T1 (enExample)
DE (1) DE60320770D1 (enExample)
DK (1) DK1485051T3 (enExample)
ES (1) ES2305457T3 (enExample)
PT (1) PT1485051E (enExample)
SI (1) SI1485051T1 (enExample)
WO (1) WO2003079945A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
UA81056C2 (en) 2003-07-25 2007-11-26 Euro Celtic S A Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
AU2012351806C1 (en) 2011-12-15 2016-06-16 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2790703B1 (en) * 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DK0484543T3 (da) * 1990-04-24 1996-01-22 Teijin Ltd Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US6165499A (en) * 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
DE60320770D1 (de) 2008-06-19
EP1485051A1 (en) 2004-12-15
PT1485051E (pt) 2008-07-09
EP1485051B1 (en) 2008-05-07
ATE394097T1 (de) 2008-05-15
US20030181475A1 (en) 2003-09-25
SI1485051T1 (sl) 2008-10-31
CY1108217T1 (el) 2014-02-12
DK1485051T3 (da) 2008-09-08
JP2005528359A (ja) 2005-09-22
EP1485051A4 (en) 2006-05-24
ES2305457T3 (es) 2008-11-01
WO2003079945A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2003224742A1 (en) Method of administering buprenorphine to treat depression
MY169308A (en) Treatment of tnf? related disorders
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
MXPA04009929A (es) Tratamiento de la gastroparesis.
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
IL173346A0 (en) Treatment of dependence withdrawal
ZA200609266B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
GB0020504D0 (en) Therapeutic method
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
UA81689C2 (ru) Способ предоперационного лечения послеоперационной боли бупренорфином
GB0405381D0 (en) A method and means for treating heart failure
AU2001236529A1 (en) Combination therapy for cancer
EP1795189A3 (en) Method of administering buprenorphine to treat depression
IL159770A0 (en) Calcium salts with cytotoxic activity
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
ATE375796T1 (de) Verwendung von devazepide als schmerzmittel
WO2001089530A3 (en) Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
簡誌銘 et al. Subacute thyroiditis associated with vocal cord paralysis: report of a case
AU2001262378A1 (en) Method for treating cryptorchidism
TNSN03022A1 (en) Method for treatment of inflammation
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
WO2000067733A3 (de) Medikament zur therapie der männlichen infertilität

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase